Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 1031-1040 of 3416 for cancer

Edit search filters
  1. A Study to Evaluate Biomarker/ALK Inhibitor Combinations in Treating Patients With Stage IV ALK Positive Non-squamous Non-small Cell Lung Cancer (The NCI-NRG ALK Protocol)

    Rochester, MN

  2. Study of RP-6306 With FOLFIRI in Advanced Solid Tumors

    Scottsdale/Phoenix, AZ, Rochester, MN

  3. A Study in Subjects with Malignant Pleural Mesothelioma to Assess ADI-PEG 20 with Pemetrexed and Cisplatin

    Rochester, MN

  4. SC Versus IV Isatuximab in Combination With Pomalidomide and Dexamethasone in RRMM

    Jacksonville, FL

  5. Alisertib in Treating Patients With Advanced or Metastatic Sarcoma

    Scottsdale/Phoenix, AZ, Rochester, MN

  6. A Study Evaluating AMG 424 in Subjects With Multiple Myeloma

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  7. A Phase I Study of TAS-102 in Patients with Advanced Solid Tumors with Renal Impairment

    Scottsdale/Phoenix, AZ

  8. Study of Safety and Tolerability of VLX600, an Iron Chelator, in Patients with Refractory Advanced Solid Tumors

    Rochester, MN

  9. Nivolumab and Ipilimumab in Treating Patients With Esophageal and Gastroesophageal Junction Adenocarcinoma Undergoing Surgery

    Rochester, MN

  10. A Study to Determine the Safety, Tolerability and Pharmacokinetics of an Anti-PD-1 Monoclonal Antibody in Subjects With Advanced Malignancies

    Rochester, MN

.

Mayo Clinic Footer